Abstract
To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.
| Original language | English |
|---|---|
| Pages (from-to) | 971-974 |
| Number of pages | 4 |
| Journal | Journal of Infectious Diseases |
| Volume | 175 |
| Issue number | 4 |
| State | Published - Apr 11 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. / Frenkel, L. M.; Cowles, M. K.; Shapiro, D. E.; Melvin, A. J.; Watts, D. H.; McLellan, C.; Mohan, K.; Murante, B.; Burchett, S.; Bryson, Y. J.; O'Sullivan, M. J.; Mitchell, Charles D; Landers, D.
In: Journal of Infectious Diseases, Vol. 175, No. 4, 11.04.1997, p. 971-974.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1
AU - Frenkel, L. M.
AU - Cowles, M. K.
AU - Shapiro, D. E.
AU - Melvin, A. J.
AU - Watts, D. H.
AU - McLellan, C.
AU - Mohan, K.
AU - Murante, B.
AU - Burchett, S.
AU - Bryson, Y. J.
AU - O'Sullivan, M. J.
AU - Mitchell, Charles D
AU - Landers, D.
PY - 1997/4/11
Y1 - 1997/4/11
N2 - To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.
AB - To gain insight into the protective effects of the three components of the zidovudine regimen used in AIDS Clinical Trial Group (ACTG) 076 on mother-to-infant transmission of human immunodeficiency virus (HIV) type 1, 188 zidovudine-treated women and their untreated infants from five HIV-1 obstetric centers were retrospectively studied. The overall rate of mother- to-infant transmission was 12.3% (95% confidence interval [CI], 7.9%- 18.0%). When the 38 women with <200 CD4 cells/μL were excluded, the mother- to-infant transmission rate was 8.8% (95% CI, 4.6%-14.8%). This rate compares favorably with the 8.3% transmission in the zidovudine arm of the ACTG 076 study. Apart from low (<200/μL) maternal CD4 cells (P = .016), no factors, including the duration of zidovudine therapy during gestation and intravenous administration of zidovudine during labor, affected the rate of mother-to-infant transmission. These findings suggest that antenatal oral zidovudine may be as effective as antenatal oral plus intravenous zidovudine during labor and the three-component ACTG 076 regimen in decreasing mother- to-infant HIV-1 transmission.
UR - http://www.scopus.com/inward/record.url?scp=16944361839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=16944361839&partnerID=8YFLogxK
M3 - Article
VL - 175
SP - 971
EP - 974
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 4
ER -